Bank of Montreal’s PMV Pharmaceuticals PMVP Stock Holding History

Bank of Montreal’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-698,184	Closed	-$4.44M	–	4131
2023 Q2	$4.44M	Buy	+698,184	New	+$3.66M	﹤0.01%	1396
2022 Q3	–	Sell	-158,368	Closed	-$2.17K	–	4353
2022 Q2	$2.17K	Buy	+158,368	New	+$2.3M	﹤0.01%	1858
2021 Q2	–	Sell	-388	Closed	-$13K	–	4632
2021 Q1	$13K	Sell	388 -1,745	-82%	-$68.8K	﹤0.01%	4241
2020 Q4	$100K	Buy	+2,133	New	+$83.7K	﹤0.01%	3581

Other funds holding PMVP

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of Montreal's PMVP Position: Q3 2023 in Review

Bank of Montreal sold out of PMV Pharmaceuticals (PMVP) in Q3 2023, closing a stake of 698,184 shares — an estimated $4.44M sold.

Bank of Montreal first reported a position in PMVP in Q4 2020 and held it in 4 quarters. The position peaked at $4.44M in Q2 2023. 104 funds tracked by Wall St. Rank hold PMVP as of Q3 2023.

Bank of Montreal reported no remaining PMV Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Bank of Montreal sold 698,184 PMV Pharmaceuticals shares in Q3 2023, an estimated $4.44M.
Bank of Montreal first reported a position in PMV Pharmaceuticals in Q4 2020 and held it in 4 quarters.
Bank of Montreal's PMV Pharmaceuticals position peaked at $4.44M in Q2 2023.
104 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q3 2023.

Based on Bank of Montreal's 13F filing for Q3 2023, filed 1 Nov 2023.